AstraZeneca, Eli Lilly and Company, and Merck are pouring a combined $12.5 billion into biopharmaceutical manufacturing projects across Virginia, sparking a wave of job creation and economic growth. Near Charlottesville, AstraZeneca's $4.5 billion investment will build a facility producing drug substances for weight-management, metabolic, and cancer treatments, generating 600 permanent jobs and 3,000 construction roles. In Goochland County, Lilly's $5 billion project will manufacture cancer and autoimmune therapies, adding 650 permanent jobs and 1,800 construction positions. Merck's $3 billion Center of Excellence for Pharmaceutical Manufacturing in Elkton will focus on small-molecule production, creating 500 full-time roles and 8,000 construction jobs.
These investments follow Virginia's rapid biopharma job growth, which surged by nearly 5,000 positions by 2024, ranking among the top five gains nationwide. The industry now supports 65,000 total jobs and contributes $20.3 billion to the state's economy. Elizabeth Carpenter, executive vice president of policy and research at PhRMA, emphasized the sector's high-paying roles and economic multiplier effect, noting that every biopharma job supports three additional positions elsewhere.
The projects highlight Virginia's competitive advantages, including skilled talent, robust infrastructure, and supportive policies. Lilly cited workforce potential, utilities, and incentives as key factors in selecting Goochland County. The state's Virginia Talent Accelerator Program further bolsters these initiatives. The investments also underscore the broader U.S. leadership in biopharmaceutical innovation, with American patients accessing 88% of new medicines compared to 36% in other high-income countries.
Beyond immediate job creation, these facilities will foster long-term career opportunities in advanced manufacturing, leveraging AI, automation, and data analytics. The projects reflect a collaborative effort among government, education, and industry to position Virginia as a leader in life sciences, with sustained policy support signaling a favorable environment for future investments.